ZURICH (Reuters) – The Swiss government said on Tuesday it had reserved up to 8,640 doses of Merck’s COVID-19 drug Molnupiravir.
The antiviral Molnupiravir should be available at the latest in January 2022, the government said in a statement, not communicating how much it has agreed to pay for the drug.
(Reporting by Silke Koltrowitz, editing by Kirsti Knolle)
